Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
US10227659B2 · kind B2 · utility
0Cited by
2References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 31, 2017 |
| Grant date | Mar 12, 2019 |
| Priority date | — |
| Expiry date | Mar 31, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.